KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer
Haoyue Sheng(Mayo Clinic), Dingwei Ye(Fudan University)
Cited by 0
Related Papers
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
|World Journal of Urology|2016|471